AngioNorm® (Angionorm®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspcoated tablets
Composition:

Each tablet, coated with a shell, contains:

Active component: AngioNorm® extract is dry (obtained from a mixture of herbal raw materials - hawthorn fruits, licorice roots, horse chestnut seeds, rosehip fruits with the content of the sum of flavonoids in terms of avicularin 0.50 mg) - 100 mg.

Excipients: lactose monohydrate - 57.00 mg, potato starch - 89.00 mg, microcrystalline cellulose - 1.00 mg, stearic acid - 3.0 mg.

The shell obtained by the method of building: sucrose - 141.10 mg, magnesium hydroxycarbonate - 27.64 mg, silicon dioxide colloid - 2.20 mg, titanium dioxide - 2.70 mg, povidone low molecular weight - 2.20 mg, talc 1.90 mg, tropeolin- O - 0.06 mg.

Mastic for gloss: beeswax - 0.10 mg, paraffin liquid - 0.10 mg.

Description:

The biconvex form of the tablet, coated with a yellow coating, shows yellow and white shells on the incision, as well as the tablet core from light brown to dark brown, bright inclusions are allowed.

Pharmacotherapeutic group:Angioprotective agent
ATX: & nbsp
  • Other lipid-lowering drugs
    • Pharmacodynamics:

    AngioNorm® has a pronounced antiaggregation, antiplatelet activity,angioprotektornoy and anti-inflammatory properties, has venotonic and microcirculation improving effect, activates diuretic renal function. AngioNorm® affects the overall health: increases physical efficiency, exhibits a stress-protective activity and a moderate analgesic effect.

    Indications:

    In the combined therapy of diseases involving vascular disorders, such as increased platelet aggregation (thrombosis, thromboembolism), impaired capillary permeability and microcirculation (capillary thrombosis), impaired venous circulation (varicose veins, post-thrombotic syndrome, thrombophlebitis).

    Contraindications:

    Increased sensitivity to the drug, severe chronic diseases of the liver, kidneys and gastrointestinal tract in violation of their functions.

    Lactase deficiency, lactose intolerance, lack of sucrase / isomaltase, fructose intolerance, glucose-galactosemalabsorption (due to the presence of lactose and sucrose).

    It is not recommended to administer the drug to children under the age of 18,during pregnancy and during breastfeeding due to the lack of data on the safety of clinical use.
    Dosing and Administration:

    AngioNorm® is taken orally 1 tablet 3 times a day 40 minutes after eating.

    Duration of treatment up to 3 weeks.

    It is possible to increase the single dose of AngioNorma® to 2 tablets 3 times a day in case of good tolerability.

    The need for a repeat course is determined by the doctor.

    Side effects:Allergic reactions, dyspeptic disorders.
    Overdose:

    With prolonged use of AngioNorma® in doses exceeding the recommended daily dose, it is possible to increase the degree of manifestation of dose-dependent side effects.

    Treatment symptomatic.

    Interaction:The use of AngioNorma® can be combined with other medicines: hypolipidemic, anti-inflammatory, analgesic, antibiotics, anticoagulants of direct and indirect action.
    Special instructions:
    Information for patients with diabetes mellitus: one tablet contains 0.023 bread units (XE), in the maximum daily dose - 0.138 bread units (XE).
    Effect on the ability to drive transp. cf.and fur:The use of the drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
    Form release / dosage:Tablets, coated with a coating, 100 mg.
    Packaging:

    10 tablets per contour cell packaging made of polyvinylchloride film and aluminum foil.

    For 30 tablets in cans of polymeric or in cans of polymeric with the control of the first opening and a shock absorber.

    By 10 contour cell packs or can of polymer together with the instructions for use are placed in a pack of cardboard

    Storage conditions:

    In a dry, dark place at a temperature of 15 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LS-001137
    Date of registration:27.05.2011 / 15.03.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:OTISIFARM, OJSC OTISIFARM, OJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspOtisipharm, PAOOtisipharm, PAORussia
    Information update date: & nbsp15.08.2017
    Illustrated instructions
      Instructions
      Up